Omnipaque (Iohexol)

Omnipaque is employed in radiographic procedures that require enhanced contrast of vascular and tissue structures.

• Angiography: Improves visualization of blood vessels for diagnostic assessment.
• Computed Tomography (CT): Provides high‑contrast images of organs and soft tissues.
• Intravenous urography: Enhances delineation of the urinary tract during X‑ray studies.
• Myelography: Facilitates clear imaging of the spinal canal and nerve roots.
• Venography: Highlights veins to detect thrombosis or obstruction.
• Endovascular interventions: Assists in real‑time imaging guidance during minimally invasive procedures.

• Iohexol is a water‑soluble, iodine‑rich compound that, when injected intravascularly, absorbs X‑ray photons more strongly than surrounding tissues. This differential absorption creates a high‑contrast outline of blood vessels and organ structures on radiographic images, allowing clinicians to differentiate anatomical details during CT, angiography, and other imaging modalities.

Adverse reactions to Omnipaque may vary in frequency and severity.

Common Side Effects

• Warmth or flushing sensation at the injection site
• Mild nausea or vomiting
• Transient headache
• Temporary metallic taste
• Mild itching or rash
• Slight increase in serum creatinine (usually reversible)

Serious or Rare Side Effects

• Severe allergic reaction (anaphylaxis)
• Acute kidney injury, especially in patients with pre‑existing renal impairment
• Cardiovascular collapse
• Pulmonary edema
• Severe hypotension
• Persistent neurological deficits (rare)

Before using Omnipaque, clinicians should assess patient risk factors and follow recommended preparation guidelines.

• Renal function assessment: Evaluate baseline creatinine and eGFR, especially in patients with known kidney disease.
• Allergy history: Review prior reactions to iodinated contrast agents or iodine‑containing substances.
• Hydration status: Ensure adequate fluid intake before and after administration to reduce nephrotoxicity risk.
• Thyroid monitoring: Be aware of potential iodine‑induced thyroid dysfunction in susceptible individuals.
• Concomitant nephrotoxic drugs: Avoid or adjust dosing of NSAIDs, aminoglycosides, or other renal‑impacting medications.
• Store at ambient temperature: Keep in original packaging, protect from light and moisture.

Omnipaque may interact with other agents that affect renal function or provoke hypersensitivity.

Major Interactions (Avoid)

• Concurrent use of high‑dose NSAIDs or other nephrotoxic drugs that can exacerbate contrast‑induced nephropathy.
• Metformin in patients with impaired renal function due to risk of lactic acidosis.

Moderate Interactions (Monitor Closely)

• Beta‑blockers or calcium‑channel blockers that may influence blood pressure responses during injection.
• Diuretics, which can alter intravascular volume and affect contrast distribution.
• Thyroid hormone replacement, requiring monitoring for iodine‑induced thyroid function changes.
• ACE inhibitors or ARBs, which may modify renal hemodynamics and necessitate closer observation.
• Radiopharmaceuticals administered in the same session, requiring timing adjustments to avoid image interference.